pharma · Diffuse Cutaneous Systemic Sclerosis · Myopia
Elan Pharmaceuticals
Elan Pharma International
Elan Pharma International is a pharma organization headquartered in EU. Primary therapeutic focus areas include Diffuse Cutaneous Systemic Sclerosis, Myopia, Sjögren’s Syndrome With Moderate-toSevere Symptom State, Breas
Treasury Building, Lower Grand Canal Street, Dublin 2, IE HQ
1969 Founded
792 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Treasury Building, Lower Grand Canal Street, Dublin 2, IE
- Founded
- 1969
- Employees
- 792
- Programs
- 18
- Drugs
- 26
- Patents
- 0
HZNP-DAZ-301
Phase 3 · small molecule · Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
HZNP-DAZ-301 for Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity is a Phase 3 program (small_molecule) at Elan Pharma International with 1 ClinicalTrials.gov record(s).
Internal code HZNP-DAZ-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Elan Pharma International
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
- Status
- active
- Trials
- 1